RT Journal Article
SR Electronic
T1 The von Willebrand Factor stamps Plasmatic Extracellular Vesicles from Glioblastoma Patients
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2021.03.25.437073
DO 10.1101/2021.03.25.437073
A1 Quentin Sabbagh
A1 Gwennan André-Grégoire
A1 Carolina Alves-Nicolau
A1 Nicolas Bidère
A1 Emmanuel Jouglar
A1 Laëtitia Guével
A1 Jean-Sébastien Frénel
A1 Julie Gavard
YR 2021
UL http://biorxiv.org/content/early/2021/03/25/2021.03.25.437073.abstract
AB Glioblastoma is a devastating tumor of the central nervous system characterized by a poor survival and an extremely dark prognosis, making its diagnosis, treatment and monitoring highly challenging. Numerous studies have highlighted extracellular vesicles (EVs) as key players of tumor growth, invasiveness and resistance, as they carry and disseminate oncogenic material in the local tumor microenvironment and at distance. However, whether their quality and quantity reflect individual health status and changes in homeostasis is still not fully elucidated. Here, we separated EVs from plasma collected at different time points alongside with the clinical management of GBM patients. Our findings confirm that plasmatic EVs could be separated and characterized with standardized protocols, thereby ensuring the reliability of measuring vesiclemia, i.e. extracellular vesicle concentration in plasma. This unveils that vesiclemia is a dynamic parameter, which could be reflecting tumor burden and/or response to treatments. Further label-free liquid chromatography tandem mass spectrometry unmasks the von Willebrand Factor (VWF) as a selective protein hallmark for GBM-patient EVs. Our data thus support the notion that EVs from GBM patients showed differential protein cargos that can be further surveyed in circulating EVs, together with vesiclemia.Competing Interest StatementThe authors have declared no competing interest.